News
Hims & Hers shares fall after a report says the FTC has investigated its cancellation policies and billing practices for over ...
Hims & Hers Health (NYSE:HIMS) stock fell 4.1% in after-hours trading on Thursday following a Bloomberg report that revealed ...
Hims & Hers is a top telehealth stock with strong revenue growth, innovative offerings, and long-term potential. Click here ...
Telehealth and wellness platform Hims & Hers Health ($HIMS) recently disappointed investors with its mixed second-quarter ...
Danish leader will face a challenging landscape among competitors ...
Novo Nordisk revealed on Monday that it will no longer work with Hims & Hers, and that direct access to Wegovy won't be available via NovoCare Pharmacy to Hims & Hers members.
Despite the setback with HIMS, CVS Caremark, a major pharmacy benefit manager, had announced that it would make Novo Nordisk’s Wegovy its preferred GLP-1 therapy for weight loss, effective July ...
Novo Nordisk is ending a partnership with Hims & Hers. The fallout comes over claims the telehealth platform sold copycat versions of the pharmaceutical giant’s weight-loss drug Wegovy.
Novo Nordisk launched the partnership through CenterWell, Humana's (HUM) mail-order pharmacy, which would dispense the drugs prescribed by three telehealth providers — one of which was Hims & ...
Novo Nordisk said Hims & Hers has “failed to adhere to the law which prohibits mass sales of compounded drugs” and accused the telehealth company of “deceptive” marketing that is putting ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback